Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study-Reference-Cited by-同舟云学术

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Published:2012-04 Issue:4 Volume:13 Page:403-411
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kantarjian Hagop,Thomas Deborah,Jorgensen Jeffrey,Jabbour Elias,Kebriaei Partow,Rytting Michael,York Sergernne,Ravandi Farhad,Kwari Monica,Faderl Stefan,Rios Mary Beth,Cortes Jorge,Fayad Luis,Tarnai Robert,Wang Sa A,Champlin Richard,Advani Anjali,O'Brien Susan

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Treatment of acute lymphoblastic leukemia;Pui;N Engl J Med,2006

2. Biology, risk stratification, and therapy of pediatric acute leukemias: an update;Pui;J Clin Oncol,2011

3. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995;Gaynon;Leukemia,2000

4. Treatment of adult ALL according to protocols of the German multicenter study group for adult ALL (GMALL);Gokbuget;Hematol Oncol Clin North Am,2000

5. Modern therapy of acute lymphoblastic leukemia;Bassan;J Clin Oncol,2011

Cited by 357 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL);Current Treatment Options in Oncology;2024-08-05

2. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions;Cancer;2024-08-02

3. Unlocking the potential of bispecific ADCs for targeted cancer therapy;Frontiers of Medicine;2024-07-23

4. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL;Blood Advances;2024-06-14

5. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions;Journal of Hematology & Oncology;2024-05-11